Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2015/295925 http://scihub22266oqcxt.onion/10.1155/2015/295925 C4584036!4584036!26448932     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Res+Int 2015 ; 2015 (ä): ä Nephropedia Template TP {{tp|p=26448932|t=2015. Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain |pdf=|usr=}}{{26448932}} gab.com Text Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26448932 #FOAvip Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5?mg/kg) or regular doses (1 or 3?mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5?mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41?mm3 for 0.5?mg/kg and 153 ± 47?mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of I?B and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation. Twit Text FOAVip Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=26448932 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26448932 #FOAvip English Wikipedia <ref>{{Cite pmid|26448932}}</ref> Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain #MMPMID26448932 Kim CK; Yang XL; Kim YJ; Choi IY; Jeong HG; Park HK; Kim D; Kim TJ; Jang H; Ko SB; Yoon BW Biomed Res Int 2015[]; 2015 (ä): ä PMID26448932show ga Fimasartan is a newly developed angiotensin receptor blocker, which may have protective effects during myocardial infarction or atherosclerosis. In this context, we investigated the effects of long-term treatment with low-dose fimasartan on focal ischemia in rat brain. We induced focal ischemia in brain by transient intraluminal occlusion of middle cerebral artery (MCA) and administered low-dose (0.5?mg/kg) or regular doses (1 or 3?mg/kg) of fimasartan via intravenous routes. After the administration of low-dose (0.5?mg/kg) fimasartan, blood pressure did not decrease compared to the phosphate-buffered saline- (PBS-) control with MCA occlusion (MCAO) group. The infarct volume and ischemic cell death were reduced in the low-dose fimasartan-treated group (46 ± 41?mm3 for 0.5?mg/kg and 153 ± 47?mm3 for PBS-control with MCAO; P < 0.01) but not in the regular-dose groups. Low-dose fimasartan treatment improved functional recovery after ischemia and significantly decreased mortality. In our study, fimasartan reduced the degradation of I?B and the formation of an inflammatory end-product, COX-2. As a result, the recruitment of inflammatory cells in the peri-infarct area decreased in fimasartan-treated group. We have demonstrated that long-term, low-dose fimasartan treatment improved outcomes after focal ischemia in the brain via a reduction of inflammation. äEffect of Long-Term Treatment with Fimasartan on Transient Focal Ische(epmc).pdf DeepDyve Pubget Overpricing